ELEVECTA™ cell lines

Transient. Packaging. Producer.

Make AAV your way.



cytiva

Elevate your gene therapy journey

With a full suite of cell lines for adeno-associated virus (AAV) manufacturing

The future of viral vector manufacturing demands a smarter approach. That starts with the right cell line. The ELEVECTA™ cell line portfolio combines innovative design and deep expertise to deliver transient, packaging, and producer options that provide high quality therapeutic AAVs and the flexibility to transition as needs evolve. Interconnected through their common parental cell line, the three options create a complete cell line portfolio, supporting regulatory and quality uniformity.

> “Our pursuit in developing a true producer cell line has yielded a significant breakthrough. It represents a culmination of scientific expertise, empowering researchers to push the boundaries of AAV development and production.”

Ben Hudjetz,

Head of Cell Technology, Viral Vectors

Designed for speed, the ELEVECTA transient cell line is an excellent choice for producing viral vectors using transient transfection. This off-the-shelf cell line allows for easy integration into existing workflows, minimizing development time to support the quick advance of promising candidates to clinical trials. The freedom to optimize the protocol and to transition to a packaging or producer cell line later maximize flexibility and preserve the option to scale with stable production.

ELEVECTA packaging cell line is **designed for versatility**, streamlining the screening of assets that use the same capsid to target the same tissue type(s). It allows easy evaluation of different genes of interest (GOI) while reducing the number of plasmids to one. The ability to quickly adapt to new gene therapy candidates provides speed and cost-effectiveness.

ELEVECTA producer cell line is **designed for transformation**. Mimicking the know-how gained from decades of work with CHO cells for monoclonal antibody production, this cell line encompasses all necessary genes into its genome for AAV stable production, eliminating the need for transfection and co-infection by an adenovirus. The resulting simplicity of the upstream process allows for seamless scalability and robustness of the manufacturing process while reducing cost of goods sold (COGS).

	ELEVECTA transient cell line	**ELEVECTA packaging cell line**	**ELEVECTA producer cell line**
Process for AAV production	 + Transfection reagent + 	 + Transfection reagent + 	No plasmid needed 
Transgene stably integrated	None	• Rep • Helper • Cap	• Rep • Helper • Cap • GOI
Plasmid needed for production	• pRepCap • pHelper • pGOI	• pGOI	None
Inducible expression	No	Yes	Yes
Order	Off-the-shelf	Custom R&D service	Custom service

Empowering therapies

Select the cell line that matches your needs as they evolve

In gene therapy, each program and therapeutic approach has its own objectives, underscoring why it's so important to select an appropriate cell line. Cytiva addresses this need with three specialized options to meet diverse requirements — from research to commercial production and from ultra-rare to prevalent indications — all supporting speed and regulatory success. This versatile portfolio empowers therapy developers to begin with our transient cell line for research and early preclinical work. For programs with low clinical and market demands, developers can continue production in the transient cell line, while those working with prevalent indications can seamlessly transition to one of our stable cell lines for clinical and commercial manufacturing needs.



> Choosing the right cell line is crucial. That's why we developed a range of options — from transient lines to stable lines for large-scale production. This lets researchers choose the right tool for the job, whether they're tackling ultra-rare or prevalent diseases.

Dovilé Woods,
Global product manager for cell line development, Viral Vectors

Push the boundaries in viral vector quality

Minimizing encapsidated host cell DNA (hcDNA)

ELEVECTA cell lines are genetically modified to minimize the encapsidation of hcDNA, a known contaminant resistant to DNase treatment and that can't be eliminated via downstream processing. ELEVECTA cell lines proactively address this concern and show our commitment to innovation and product quality.

Helper virus-free stable cell lines

Moreover, our stable cell lines don't need any helper viruses such as herpes or adeno viruses in AAV production, thus eliminating the risk of these viruses contaminating the final product. The absence of helper viruses removes the requirement to either test each purified bulk product for this process-related impurity or validate excess clearance specific to the helper virus. Process validation and design for clearance become simpler without the addition of such helper viruses, giving you the peace of mind that you need going into clinical trials.



Collaborating for success

We understand that success goes beyond just our product

Flexible agreements: Your therapy is unique. Our licensing terms are flexible, allowing us to tailor agreements to accommodate your specific needs and project requirements.

Competitive pricing: We strive to make cutting-edge technologies accessible. Our licensing terms are transparent and designed to be competitive, aimed at providing you with access to our solutions without compromising your budget.

Collaborative support: Your success is our success. We offer technical support throughout the licensing process to ensure a smooth and efficient experience. Our dedicated team is here to address any questions or concerns you may have.



Navigate regulatory complexities with confidence

As an optional fee-based service, clients that adopt our cell lines can access a comprehensive suite of regulatory support services designed to expedite their success in advancing to and through clinical trials. This includes providing review briefing documents and presentations for FDA/European Medicines Agency (EMA) meetings. Leveraging the expertise of our regulatory thought leaders, we provide valuable strategic information to navigate the regulatory landscape effectively. Our support extends to the access of drug master files (DMFs) for ELEVECTA cell lines to help accelerate our clients' journey into the clinic, fostering an efficient regulatory process.

cytiva.com

For local office contact information, visit cytiva.com/contact

CY43113-19Sep25-BR

cytiva